5AM Venture Management, LLC
13F Reported Value
ⓘ$287.9M
Holdings
16
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
5AM Venture Management, LLC disclosed 16 positions worth $287.9M in its Form 13F-HR for Q2 2026, led by $MPLT (MapLight Therapeutics, Inc.) at 11.8% of the equity portfolio, followed by $TYRA and $TRDA. During the quarter the fund opened 0 new positions and exited 4 and a full exit from $ERAS. The portfolio is most concentrated in Healthcare (94.8% of disclosed assets). All figures are sourced directly from 5AM Venture Management, LLC’s Form 13F-HR filing with the SEC under CIK 1799883.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$34.0M950,011 sh - —
Quality
$32.9M1,029,298 sh - 7.3#2,948
Quality
$29.9M4,056,379 sh - —
Quality
$27.6M797,600 sh - 25.3
Quality
$25.6M5,869,091 sh - 9.7
Quality
$22.8M2,353,304 sh - —
Quality
$20.9M606,660 sh - 11.6
Quality
$19.1M3,947,913 sh - 8.4
Quality
$18.5M497,270 sh - 3.5
Quality
$15.0M1,050,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 MapLight Therapeutics, Inc.$MPLT | — | $34.0M | 950,011 |
 Tyra Biosciences, Inc.$TYRA | — | $32.9M | 1,029,298 |
 Entrada Therapeutics, Inc.$TRDA | 7.3#2,948 | $29.9M | 4,056,379 |
 Pharvaris N.V.$PHVS | — | $27.6M | 797,600 |
 Camp4 Therapeutics Corp$CAMP | 25.3 | $25.6M | 5,869,091 |
 Artiva Biotherapeutics, Inc.$ARTV | 9.7 | $22.8M | 2,353,304 |
 Tectonic Therapeutic, Inc.$TECX | — | $20.9M | 606,660 |
 Zentalis Pharmaceuticals, Inc.$ZNTL | 11.6 | $19.1M | 3,947,913 |
 Celldex Therapeutics, Inc.$CLDX | 8.4 | $18.5M | 497,270 |
 EyePoint, Inc.$EYPT | 3.5 | $15.0M | 1,050,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of 5AM Venture Management, LLC's 16 positions.
Showing top 10 of 16 holdings.
Sector Allocation
Healthcare
$272.9M
Technology
$15.0M
Full Holdings — 5AM Venture Management, LLC (Q2 2026)
All 16 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $MPLT | MapLight Therapeutics, Inc. | $34.0M | 11.8% | +0% | — |
| 2 | $TYRA | Tyra Biosciences, Inc. | $32.9M | 11.4% | +0% | — |
| 3 | $TRDA | Entrada Therapeutics, Inc. | $29.9M | 10.4% | +0% | 7.3 |
| 4 | $PHVS | Pharvaris N.V. | $27.6M | 9.6% | +0% | — |
| 5 | $CAMP | Camp4 Therapeutics Corp | $25.6M | 8.9% | +0% | 25.3 |
| 6 | $ARTV | Artiva Biotherapeutics, Inc. | $22.8M | 7.9% | +0% | 9.7 |
| 7 | $TECX | Tectonic Therapeutic, Inc. | $20.9M | 7.2% | +0% | — |
| 8 | $ZNTL | Zentalis Pharmaceuticals, Inc. | $19.1M | 6.7% | +0% | 11.6 |
| 9 | $CLDX | Celldex Therapeutics, Inc. | $18.5M | 6.4% | +0% | 8.4 |
| 10 | $EYPT | EyePoint, Inc. | $15.0M | 5.2% | +0% | 3.5 |
| 11 |  $BHVN | Biohaven Ltd. | $11.0M | 3.8% | +0% | — |
| 12 |  $SRZN | Surrozen, Inc./DE | $7.0M | 2.4% | -30% | — |
| 13 |  $SKYE | Skye Bioscience, Inc. | $6.7M | 2.3% | +0% | — |
| 14 |  $ALXO | ALX ONCOLOGY HOLDINGS INC | $6.3M | 2.2% | +0% | — |
| 15 |  $TARA | Protara Therapeutics, Inc. | $5.2M | 1.8% | +0% | — |
| 16 |  $SLN | Silence Therapeutics plc | $5.2M | 1.8% | +0% | — |
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for 5AM Venture Management, LLC including:
Track 5AM Venture Management, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for 5AM Venture Management, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: 5AM Venture Management, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For 5AM Venture Management, LLC (SEC CIK: 1799883), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in 5AM Venture Management, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.